The US company's proprietary CHoMP platform (Co-culture with Human Myeloid Phagocytes) uses CRISPR-based functional genomic screens in human cancer cells and/or primary macrophages to discover and validate new DEM and EM signals that could profoundly induce and enhance cancer cell elimination through increased phagocytosis.

In September 2022, long-time Takeda exec Nenad Grmusa was named the company's chief executive. The firm only launched earlier in 2022 with $70 million in financing led by founding investor Longwood Fund and Alta Partners.